Do analysts prefer BLRX or CRIS?

Curis has a consensus price target of $43.00, indicating a potential upside of 3,085.19%. Given Curis' stronger consensus rating and higher probable upside, analysts clearly believe Curis is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curis 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is BLRX or CRIS more profitable?

Curis has a net margin of -80.29% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -502.08% -34.80% -18.27% Curis -80.29% -2,365.94% -200.88%

Is CRIS or PDSB more profitable?

PDS Biotechnology has a net margin of 0.00% compared to Curis' net margin of -80.29%. PDS Biotechnology's return on equity of -708.18% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% -2,365.94% -200.88% PDS Biotechnology N/A -708.18% -136.50%

Is CRIS or SNTI more profitable?

Senti Biosciences has a net margin of 0.00% compared to Curis' net margin of -80.29%. Senti Biosciences' return on equity of -1,629.80% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% -2,365.94% -200.88% Senti Biosciences N/A -1,629.80% -119.72%

Is CRIS or APRE more profitable?

Curis has a net margin of -80.29% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% -2,365.94% -200.88% Aprea Therapeutics -4,405.59% -47.60% -40.97%

Which has higher valuation and earnings, CRIS or INAB?

Curis has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curis $9.44M 0.30 -$7.58M -$14.22 N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is CRIS or INAB more profitable?

IN8bio has a net margin of 0.00% compared to Curis' net margin of -80.29%. IN8bio's return on equity of -91.18% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% -2,365.94% -200.88% IN8bio N/A -91.18% -76.93%

Curis (CRIS) Competitors

$1.35 -0.02 (-1.46%)

As of 04:00 PM Eastern

Compare

CRIS vs. BLRX, PDSB, SNTI, APRE, and INAB

Should you buy Curis stock or one of its competitors? Curis's main competitors and comparable companies include BioLineRx (BLRX), PDS Biotechnology (PDSB), Senti Biosciences (SNTI), Aprea Therapeutics (APRE), and IN8bio (INAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Curis compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Curis (NASDAQ:CRIS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 5.8% of Curis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Curis has a net margin of -80.29% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-502.08%	-34.80%	-18.27%
Curis	-80.29%	-2,365.94%	-200.88%

Curis has a consensus price target of $43.00, indicating a potential upside of 3,085.19%. Given Curis' stronger consensus rating and higher probable upside, analysts clearly believe Curis is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

BioLineRx has higher earnings, but lower revenue than Curis. BioLineRx is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	9.89	-$1.17M	-$1.69	N/A
Curis	$9.44M	0.30	-$7.58M	-$14.22	N/A

BioLineRx has a beta of 1.56, indicating that its stock price is 56% more volatile than the broader market. Comparatively, Curis has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market.

In the previous week, BioLineRx had 12 more articles in the media than Curis. MarketBeat recorded 12 mentions for BioLineRx and 0 mentions for Curis. BioLineRx's average media sentiment score of 0.08 beat Curis' score of 0.00 indicating that BioLineRx is being referred to more favorably in the media.

Company	Overall Sentiment
BioLineRx	Neutral
Curis	Neutral

Summary

Curis beats BioLineRx on 9 of the 16 factors compared between the two stocks.

How does Curis compare to PDS Biotechnology?

Curis (NASDAQ:CRIS) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

In the previous week, PDS Biotechnology had 1 more articles in the media than Curis. MarketBeat recorded 1 mentions for PDS Biotechnology and 0 mentions for Curis. PDS Biotechnology's average media sentiment score of 0.71 beat Curis' score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Curis	Neutral
PDS Biotechnology	Positive

Curis currently has a consensus price target of $43.00, suggesting a potential upside of 3,085.19%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 3,990.91%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe PDS Biotechnology is more favorable than Curis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Curis has a beta of 3.01, meaning that its share price is 201% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

30.0% of Curis shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 5.8% of Curis shares are owned by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PDS Biotechnology has a net margin of 0.00% compared to Curis' net margin of -80.29%. PDS Biotechnology's return on equity of -708.18% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	-2,365.94%	-200.88%
PDS Biotechnology	N/A	-708.18%	-136.50%

Curis has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.30	-$7.58M	-$14.22	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.64	N/A

Summary

PDS Biotechnology beats Curis on 10 of the 15 factors compared between the two stocks.

How does Curis compare to Senti Biosciences?

Curis (NASDAQ:CRIS) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

30.0% of Curis shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 5.8% of Curis shares are held by company insiders. Comparatively, 3.1% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Curis currently has a consensus price target of $43.00, suggesting a potential upside of 3,085.19%. Senti Biosciences has a consensus price target of $10.00, suggesting a potential upside of 2,906.61%. Given Curis' higher probable upside, equities research analysts plainly believe Curis is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Curis has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market.

Senti Biosciences has a net margin of 0.00% compared to Curis' net margin of -80.29%. Senti Biosciences' return on equity of -1,629.80% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	-2,365.94%	-200.88%
Senti Biosciences	N/A	-1,629.80%	-119.72%

Curis has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.30	-$7.58M	-$14.22	N/A
Senti Biosciences	$20K	518.02	-$61.44M	-$1.77	N/A

In the previous week, Curis' average media sentiment score of 0.00 equaled Senti Biosciences'average media sentiment score.

Company	Overall Sentiment
Curis	Neutral
Senti Biosciences	Neutral

Summary

Senti Biosciences beats Curis on 8 of the 15 factors compared between the two stocks.

How does Curis compare to Aprea Therapeutics?

Curis (NASDAQ:CRIS) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Curis has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.30	-$7.58M	-$14.22	N/A
Aprea Therapeutics	$290K	34.48	-$12.60M	-$1.08	N/A

Curis has a net margin of -80.29% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	-2,365.94%	-200.88%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Curis has a beta of 3.01, suggesting that its stock price is 201% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

In the previous week, Aprea Therapeutics' average media sentiment score of 0.07 beat Curis' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Curis	Neutral
Aprea Therapeutics	Neutral

Curis presently has a consensus target price of $43.00, indicating a potential upside of 3,085.19%. Aprea Therapeutics has a consensus target price of $3.07, indicating a potential upside of 286.08%. Given Curis' higher probable upside, research analysts clearly believe Curis is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

30.0% of Curis shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 5.8% of Curis shares are owned by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Aprea Therapeutics beats Curis on 9 of the 15 factors compared between the two stocks.

How does Curis compare to IN8bio?

Curis (NASDAQ:CRIS) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

IN8bio has a net margin of 0.00% compared to Curis' net margin of -80.29%. IN8bio's return on equity of -91.18% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	-2,365.94%	-200.88%
IN8bio	N/A	-91.18%	-76.93%

Curis has a beta of 3.01, indicating that its stock price is 201% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

In the previous week, Curis' average media sentiment score of 0.00 equaled IN8bio'saverage media sentiment score.

Company	Overall Sentiment
Curis	Neutral
IN8bio	Neutral

Curis has higher revenue and earnings than IN8bio. IN8bio is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.30	-$7.58M	-$14.22	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Curis currently has a consensus price target of $43.00, indicating a potential upside of 3,085.19%. IN8bio has a consensus price target of $4.00, indicating a potential upside of 233.33%. Given Curis' higher probable upside, equities analysts plainly believe Curis is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.0% of Curis shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 5.8% of Curis shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

IN8bio beats Curis on 7 of the 12 factors compared between the two stocks.

Get Curis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRIS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRIS vs. The Competition

Export

Metric	Curis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.82M	$3.98B	$7.17B	$12.88B
Dividend Yield	N/A	3.60%	2.53%	8.57%
P/E Ratio	-0.09	12.71	272.99	25.40
Price / Sales	0.30	1,325.73	612.73	97.75
Price / Cash	N/A	106.87	77.82	52.27
Price / Book	0.60	16.15	12.85	6.17
Net Income	-$7.58M	-$22.76M	$3.47B	$349.50M
7 Day Performance	-9.40%	1.13%	1.24%	-0.05%
1 Month Performance	-71.40%	8.93%	5.81%	0.80%
1 Year Performance	-96.05%	52.96%	25.75%	15.62%

Curis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRIS Curis	1.675 of 5 stars	$1.35 -1.5%	$43.00 +3,085.2%	-96.0%	$2.82M	$9.44M	N/A	60	Gap Down
BLRX BioLineRx	0.6807 of 5 stars	$2.84 -5.3%	N/A	-25.9%	$12.41M	$1.40M	N/A	40	News Coverage Earnings Report Analyst Revision
PDSB PDS Biotechnology	2.6648 of 5 stars	$0.22 +1.5%	$9.00 +3,990.9%	-83.1%	$12.31M	N/A	N/A	20
SNTI Senti Biosciences	2.9034 of 5 stars	$0.39 +3.2%	$10.00 +2,464.1%	-76.4%	$12.24M	$55K	N/A	4	Gap Up
APRE Aprea Therapeutics	3.1993 of 5 stars	$0.97 +20.1%	$3.07 +217.1%	-47.3%	$12.16M	$290K	N/A	7	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRIS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curis (CRIS) Competitors

CRIS vs. BLRX, PDSB, SNTI, APRE, and INAB

How does Curis compare to BioLineRx?

Summary

How does Curis compare to PDS Biotechnology?

Summary

How does Curis compare to Senti Biosciences?

Summary

How does Curis compare to Aprea Therapeutics?

Summary

How does Curis compare to IN8bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curis (CRIS) Competitors

CRIS vs. BLRX, PDSB, SNTI, APRE, and INAB

How does Curis compare to BioLineRx?

Do institutionals & insiders have more ownership in BLRX or CRIS?

Is BLRX or CRIS more profitable?

Do analysts prefer BLRX or CRIS?

Which has higher earnings & valuation, BLRX or CRIS?

Which has more risk & volatility, BLRX or CRIS?

Does the media prefer BLRX or CRIS?

Summary

How does Curis compare to PDS Biotechnology?

Does the media refer more to CRIS or PDSB?

Do analysts prefer CRIS or PDSB?

Which has more risk and volatility, CRIS or PDSB?

Do institutionals and insiders hold more shares of CRIS or PDSB?

Is CRIS or PDSB more profitable?

Which has stronger earnings and valuation, CRIS or PDSB?

Summary

How does Curis compare to Senti Biosciences?

Do insiders & institutionals hold more shares of CRIS or SNTI?

Do analysts recommend CRIS or SNTI?

Which has more risk and volatility, CRIS or SNTI?

Is CRIS or SNTI more profitable?

Which has better earnings and valuation, CRIS or SNTI?

Does the media refer more to CRIS or SNTI?

Summary

How does Curis compare to Aprea Therapeutics?

Which has preferable earnings & valuation, CRIS or APRE?

Is CRIS or APRE more profitable?

Which has more risk & volatility, CRIS or APRE?

Does the media favor CRIS or APRE?

Do analysts rate CRIS or APRE?

Do insiders & institutionals believe in CRIS or APRE?

Summary

How does Curis compare to IN8bio?

Is CRIS or INAB more profitable?

Which has more volatility and risk, CRIS or INAB?

Does the media favor CRIS or INAB?

Which has higher valuation and earnings, CRIS or INAB?

Do analysts recommend CRIS or INAB?

Do insiders & institutionals have more ownership in CRIS or INAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRIS vs. The Competition

Curis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools